Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Mizuho Reiterates Neutral on ACADIA Pharmaceuticals, Maintains $19 Price Target

Mizuho Reiterates Neutral on ACADIA Pharmaceuticals, Maintains $19 Price Target

Mizuho analyst Uy Ear reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and maintains $19 price target.

byBenzinga Newsdesk

March 13, 2023

1 minute read

Mizuho analyst Uy Ear reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and maintains $19 price target.

The S&P 500 Seesaws On Debt Ceiling Uncertainty, Nvidia Becomes The Street’s Favorite AI Provider

By Natan Ponieman

May 26, 4:03 PM

The S&P 500 recovered some of its losses Friday after a rollercoaster that took the index to a…

DELL

News

InvoiceCloud Announces New Integrated Solution With Oracle Energy And Water

By Benzinga Newsdesk

October 26, 9:19 AM

Partners aim to enhance the payment experience for mutual utility customersInvoiceCloud, an EngageSmart ((ESMT) solution for online bill payment services, has announced a new integrated solution with Oracle Energy and

ESMT

Netflix Price Hike Shocks US, UK, France: How Rival Streaming Giants Are Faring

By Ananya Gairola

October 19, 1:39 AM

Netflix's decision to raise prices came in tandem with an increase in new customer sign-ups, defying expectations.

DIS

Fed’s Waller Says Soft Landing A Plausible Outcome For U.S. Labor Market

By Benzinga Newsdesk

July 29, 9:33 AM

-Bloomberg

SPY

Mizuho Reiterates Neutral on ACADIA Pharmaceuticals, Maintains $19 Price Target

Related Posts

The S&P 500 Seesaws On Debt Ceiling Uncertainty, Nvidia Becomes The Street’s Favorite AI Provider

InvoiceCloud Announces New Integrated Solution With Oracle Energy And Water

Netflix Price Hike Shocks US, UK, France: How Rival Streaming Giants Are Faring

Fed’s Waller Says Soft Landing A Plausible Outcome For U.S. Labor Market